Federal Circuit Evaluates PTAB Ruling’s Impact on Liquidia Technologies’ Hypertension Drug Launch

A Federal Circuit panel on Tuesday grappled with the implications of a Delaware judge’s decision concerning Liquidia Technologies’ ability to launch a hypertension drug. The controversy centers on whether Liquidia could go forward with the launch after a United Therapeutics patent, which the company was previously found to infringe, was deemed unpatentable by the Patent Trial and Appeal Board (PTAB). The judicial review highlights the intricate interplay between PTAB rulings and subsequent district court decisions. For a deeper look into the case, more details are available through Law360.